$1.47 Billion is the total value of Paradigm Biocapital Advisors LP's 31 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $136,051,492 | +9.1% | 2,025,480 | +12.2% | 9.23% | -4.2% |
| ARGX | Buy | ARGENX SEsponsored adr | $128,533,222 | +131.8% | 261,443 | +83.8% | 8.72% | +103.6% |
| Buy | ARCELLX INC | $105,958,017 | +42.8% | 2,953,122 | +25.8% | 7.19% | +25.4% | |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $96,374,460 | +186.1% | 7,803,600 | +109.2% | 6.54% | +151.2% |
| Buy | NUVALENT INC | $75,305,618 | +59.4% | 1,638,147 | +46.2% | 5.11% | +40.0% | |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $73,173,948 | +44.4% | 3,642,307 | +83.5% | 4.96% | +26.8% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $72,663,133 | +39.3% | 1,668,116 | +15.5% | 4.93% | +22.3% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $71,865,203 | -5.6% | 1,384,686 | +9.0% | 4.88% | -17.1% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $69,413,013 | +31.9% | 307,314 | +28.9% | 4.71% | +15.8% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $64,795,638 | +157.8% | 2,178,737 | +56.2% | 4.40% | +126.4% |
| New | DISC MEDICINE INC | $59,771,667 | – | 1,272,279 | +100.0% | 4.06% | – | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $56,477,999 | -1.7% | 3,681,747 | +52.4% | 3.83% | -13.7% |
| CERE | Buy | CEREVEL THERAPEUTICS HLDNG I | $55,294,779 | -6.9% | 2,532,972 | +35.5% | 3.75% | -18.3% |
| INCY | Sell | INCYTE CORP | $52,714,952 | -38.7% | 912,497 | -34.0% | 3.58% | -46.2% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $50,961,084 | +33.8% | 1,491,835 | +50.8% | 3.46% | +17.5% |
| AMAM | Buy | AMBRX BIOPHARMA INCsponsored ads | $40,118,854 | +47.7% | 3,488,596 | +111.4% | 2.72% | +29.7% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $34,703,918 | -31.6% | 2,390,077 | -1.4% | 2.36% | -39.9% |
| AUTL | Buy | AUTOLUS THERAPEUTICS PLCspon ads | $33,567,802 | +53.0% | 14,406,782 | +56.3% | 2.28% | +34.4% |
| TGTX | New | TG THERAPEUTICS INC | $30,254,965 | – | 3,619,015 | +100.0% | 2.05% | – |
| ZLAB | Buy | ZAI LAB LTDadr | $27,771,331 | +15.7% | 1,142,383 | +32.0% | 1.88% | +1.7% |
| ALPN | Sell | ALPINE IMMUNE SCIENCES INC | $27,728,957 | +11.3% | 2,421,743 | -0.1% | 1.88% | -2.2% |
| IMTX | Buy | IMMATICS N.V | $23,836,816 | +4.1% | 2,058,447 | +3.7% | 1.62% | -8.6% |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $15,100,842 | -20.1% | 926,432 | +3.6% | 1.02% | -29.8% |
| New | CARIBOU BIOSCIENCES INC | $14,074,772 | – | 2,944,513 | +100.0% | 0.96% | – | |
| VOR | VOR BIOPHARMA INC | $13,698,310 | -31.4% | 6,461,467 | 0.0% | 0.93% | -39.7% | |
| New | ROIVANT SCIENCES LTD | $12,635,039 | – | 1,081,767 | +100.0% | 0.86% | – | |
| KURA | Buy | KURA ONCOLOGY INC | $11,060,991 | +4.0% | 1,212,828 | +20.7% | 0.75% | -8.6% |
| CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $10,054,447 | – | 1,358,709 | +100.0% | 0.68% | – |
| ETNB | New | 89BIO INCcall | $5,081,304 | – | 329,100 | +100.0% | 0.34% | – |
| AMAM | New | AMBRX BIOPHARMA INCcall | $2,410,400 | – | 209,600 | +100.0% | 0.16% | – |
| COGT | New | COGENT BIOSCIENCES INC | $2,199,649 | – | 225,605 | +100.0% | 0.15% | – |
| Exit | THESEUS PHARMACEUTICALS INC | $0 | – | -1,950,327 | -100.0% | -1.41% | – | |
| Exit | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $0 | – | -369,615 | -100.0% | -1.46% | – | |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -1.52% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -1,014,239 | -100.0% | -1.92% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -216,093 | -100.0% | -2.98% | – |
| ARGX | Exit | ARGENX SEput | $0 | – | -150,000 | -100.0% | -4.52% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -283,605 | -100.0% | -4.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.